Welcome to the 6th Antifibrotic Drug Development Summit

Returning for the 6th year, the Antifibrotic Drug Development Summit (AFDD) will host the transferrable insights you need from professionals working in lung fibrosis, kidney fibrosis, liver fibrosis, and many more, at one place at one time, so you can advance the progress of your antifibrotic therapies.

From delving into incorporating repair and regeneration into your antifibrotic to exploring cellular mechanisms to identify a common fibrotic pathway and bridging the translational gap to prove early therapeutic effectiveness; this unique cross-organ, cross-disease, cross-discipline discussion forum is here to transform your fibrosis research.

Join 100+ industry super giants from Boehringer Ingelheim, Genentech, Gilead, Pfizer, Novartis, and many more in Boston to harness the knowledge you need for your 2022/23 antifibrotic research and drug development.

Access the online agenda here.